BRIDGEWATER, N.J., Sept. 14, 2016 /PRNewswire/ -- Nevakar LLC, a privately-held specialty pharmaceutical company developing innovative products focused on therapies within the injectable and ophthalmic space, today announced that Gregory L. Larkin, M.D., MS, MSPH, FACEP, FACEM has joined the company in the newly created position of Vice President, Clinical Development.
"Dr. Larkin brings to Nevakar a deep understanding of the drug development and approval process, having spent more than 25 years as a practicing physician, researcher and chemical engineer, and having worked with international government agencies including the U.S. Food and Drug Administration (FDA), National Institutes of Health (NIH), Centers for Disease Control (CDC), World Health Organization (WHO), and the UK's Department of Health/National Health Service," stated Navneet Puri, Ph.D., Founder and Chief Executive Officer of Nevakar. "During his career, he has also established a number of innovative, new approaches to completing clinical trials, both ahead of schedule and under budget. We look forward to leveraging his extensive expertise as we build out our pipeline."
"Having recently completed a significant financing, Nevakar is in a prime position to progress and expand its product pipeline," stated Dr. Larkin. "I am delighted to join the Nevakar team at this critical juncture and am committed to developing enhanced therapies using currently approved molecules in order to address key, unmet clinical needs."
In addition to his role at Nevakar, Dr. Larkin is currently Adjunct Professor of Psychiatry at New York University School of Medicine. Prior, Dr. Larkin held the distinction of Inaugural Lion Foundation Professor and Chair of Emergency Medicine at the University of Auckland. He also served as Vice Chair of Emergency Medicine at Yale University School of Medicine, where he was named Inaugural Professor in the Division of Emergency Medicine. Before that, Dr. Larkin held the position of Vice Chair of Emergency Medicine at UT Southwestern Medical Center at Dallas.
Dr. Larkin is a globally recognized leader in the field of emergency and resuscitation medicine, disaster care, injury/suicide prevention, bioethics and public health, and was named an Atlantic Fellow in Public Policy for HMS Government in Whitehall under Prime Minister Tony Blair and continues to serve the UK's Department of Health/National Health Service in this capacity. Throughout his career, Dr. Larkin has received significant grant support from private, state and federal agencies.
Dr. Larkin earned his Medical Degree from Pennsylvania State University College of Medicine. He also holds Master degrees in chemical engineering and molecular biology, as well as in public health, and was awarded an honorary Master of Arts degree from Yale University.
Nevakar is a specialty pharmaceutical company focused on therapies within the injectable and ophthalmic space. Our goal is to develop enhanced products that address unmet clinical and/or commercial needs of currently FDA-approved molecules, through intensive R&D and clinical efforts. Nevakar has a comprehensive infrastructure for product development at its New Jersey facilities. More information about Nevakar can be found at www.nevakar.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nevakar-appoints-dr-gregory-l-larkin-as-vice-president-clinical-development-300327646.html
SOURCE Nevakar LLC